Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the R&D spend buried in a 300-page report or tracing how device recalls affect margins can slow any analysis. Dentsply Sirona SEC filings explained simply is exactly what busy investors need.
Our platform ingests every Dentsply Sirona annual report 10-K simplified, Dentsply Sirona quarterly earnings report 10-Q filing, and surprise notice so you see the essentials first. Stock Titan’s AI highlights which product lines—consumables, CAD/CAM, or imaging—drove revenue shifts, and flags any Dentsply Sirona 8-K material events explained within minutes of hitting EDGAR. Need deeper context? Click for a concise Dentsply Sirona earnings report filing analysis that breaks out geographic sales and regulatory commentary.
Monitoring management moves is just as seamless. Receive alerts on Dentsply Sirona insider trading Form 4 transactions and watch Dentsply Sirona Form 4 insider transactions real-time to spot buying or selling patterns before the market reacts. Our dashboards also chart Dentsply Sirona executive stock transactions Form 4 against upcoming product launches, while the latest Dentsply Sirona proxy statement executive compensation is distilled into clear compensation ratios.
Whether you’re understanding Dentsply Sirona SEC documents with AI for a valuation model or verifying compliance disclosures, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-8, DEF 14A—backed by AI-powered summaries, keyword search, and real-time updates. Spend less time parsing, and more time deciding.
DENTSPLY SIRONA (XRAY) reported an insider transaction by President & CEO and Director Daniel T. Scavilla. On 10/10/2025, he acquired 223.681 restricted stock units (RSUs) at $0, recorded as dividend equivalents on existing RSUs. Following this, his beneficial ownership stands at 17,698.73 shares, held directly.
The filing notes these RSU dividends carry the same vesting schedule as the underlying awards, and each RSU converts to one share of common stock upon vesting.
DENTSPLY SIRONA (XRAY) filed a Form 4 for an executive equity accrual. On
The filing also reports 40.5116 phantom stock units under the SERP acquired at
DENTSPLY SIRONA (XRAY) reported an initial statement of beneficial ownership for executive Aldo Mariano Roberto Denti. The filing notes he serves as EVP, Chief Commercial Officer and indicates no securities are beneficially owned.
The Form 3 lists the Date of Event as 10/06/2025 and was filed by a single reporting person. An Exhibit 24 Power of Attorney is included, with the form signed by an attorney-in-fact on the executive’s behalf.
DENTSPLY SIRONA (XRAY) director filed a Form 4 reporting RSU dividend equivalents. On 10/10/2025, the reporting person acquired 286.094 restricted stock units as dividends on existing RSUs at a price of $0. Following this transaction, beneficial ownership stands at 40,897.4765 shares, held directly.
The company states these are dividends on RSUs awarded to the reporting person, delivered as additional RSUs that carry the same vesting terms as the underlying awards. Each RSU converts to common stock on a 1:1 basis, and the dividend RSUs vest simultaneously with the related RSUs.
DENTSPLY SIRONA (XRAY) director Brian T. Gladden reported an automatic credit of 286.094 additional RSUs on 10/10/2025 at $0, reflecting dividend equivalents on prior RSU awards. Each RSU converts 1:1 into common stock and follows the same vesting schedule as the underlying awards. After this entry, his beneficial ownership stood at 28,726.563 shares, held directly.
DENTSPLY SIRONA (XRAY) director reported an equity change tied to restricted stock units. On 10/10/2025, the reporting person acquired 223.681 RSU dividend equivalents at $0. According to the footnote, these represent dividends on RSUs credited as additional RSUs, vesting on the same schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.
Following this transaction, the reporting person beneficially owned 17,699.171 shares, held directly.
DENTSPLY SIRONA (XRAY) reported an insider transaction by its EVP & CFO. On 10/10/2025, the officer acquired 556.226 shares (Transaction Code A) at $0. A footnote explains these represent dividend equivalents on previously granted RSUs, issued as additional RSUs that vest on the same schedule as the underlying awards and convert to common stock on a 1:1 basis.
After this transaction, the reporting person beneficially owned 44,011.347 shares, held directly.
DENTSPLY SIRONA (XRAY) director reported routine equity accruals. On 10/10/2025, the reporting person acquired 359.576 shares of common stock at $0 as dividend equivalents on previously granted RSUs. Following this transaction, directly held common stock totaled 28,451.376 shares.
The filing also shows an acquisition of 123.3618 units of phantom stock under the Directors' Deferred Compensation plan at a derivative price of $11.98. Phantom stock represents the economic equivalent of common stock and becomes payable in shares upon the director’s termination of service. After this accrual, the director held 11,743.5642 phantom stock units.
Notes clarify these were dividend-related accruals for RSUs and phantom stock, with RSUs converting to common stock on a 1:1 basis and phantom stock payable in common stock upon termination.
DENTSPLY SIRONA (XRAY) director reported an equity accrual. On 10/10/2025, the reporting person acquired 179.449 units at $0, reflecting dividends credited on previously awarded RSUs that carry the same vesting terms. Each RSU converts to common stock on a 1:1 basis.
Following this transaction, beneficial ownership stood at 48,005.925 on a direct basis. These credits represent routine dividend equivalents tied to outstanding RSUs rather than open‑market purchases.
DENTSPLY SIRONA (XRAY): Form 4 insider transaction by a director. On 10/10/2025, 310.397 shares of common stock were acquired at $0 as dividends on restricted stock units credited to a Family Partnership. Following this, beneficial holdings were 24,357.397 shares indirect by Family Partnership, 82,301.434 shares direct, and 21,000 shares indirect by a Gregory Lucier IRA.
On 10/14/2025, the reporting person made a gift (Code G) of 17,200 non‑qualified stock options with a $12.96 exercise price to a Family Partnership. These options are exercisable beginning 08/08/2026 and expire on 08/08/2035. The filing notes the gift and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
FAQ
What is the current stock price of Dentsply Sirona (XRAY)?
What is the market cap of Dentsply Sirona (XRAY)?
